Schnitzler syndrome: A review of literature, the authors’ observation, and experience with the interleukin-1 inhibitor canakinumab


Cite item

Full Text

Abstract

The paper reviews the publications dealing with Schnitzler syndrome, a rare autoinflammatory disease, and describes the authors’ own clinical observation. It describes the first Russian experience in successfully using the interleukin-1 inhibitor canakinumab to treat this disease.

About the authors

S O Salugina

ФГБНУ «НИИ ревматологии им. В.А. Насоновой»

Москва, Россия

V R Gorodetsky

ФГБНУ «НИИ ревматологии им. В.А. Насоновой»

Москва, Россия

E S Fedorov

ФГБНУ «НИИ ревматологии им. В.А. Насоновой»

Москва, Россия

N E Lopatina

ФГБНУ «НИИ ревматологии им. В.А. Насоновой»

Москва, Россия

M D Evsikova

ФГБНУ «НИИ ревматологии им. В.А. Насоновой»

Москва, Россия

References

  1. Simon A, Asli B, Braun-Falco M et al. Schnitzler Syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68:562-568.
  2. Lipsker D, Veran Y, Grunenberger F et al. The Schnitzler Syndrome Four new cases and review of the literature. Medicine. 2001;80:37-44.
  3. De Koning HD., Bodar EJ., van der Meer JW. Schnitzler Syndrome Study Group. Schnitzler Syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum. 2007;37:137-148.
  4. Schnitzler L, Schubert B,Boasson M et al. Urticaire chronique, lesions osseuses, macroglobulinemie IgM maladie de Waldenstrom. Bull Soc Franc Derm Syph. 1974;81:363.
  5. Lipsker D. The Schnitzler syndrome Orphanet Journal of Rare Diseases. 2010;5:38-45.
  6. Saurat JH, Schifferly J, Steiger G et al. Anti-interleukin-1 alpha autoantibodies in humans: characterization, isotype distribution and receptor-binding inhibition-higher frequency in Schnitzler’s syndrome (urticaria and macroglobulinemia). J Allergy Clin Immunol. 1991;88:244-56.
  7. Sokumbi O, Drage LA, Peters MS. Clinical and histopathologic review of Schnitzler syndrome: the Mayo Clinic experience (1972-2011). J Am Acad Dermatol. 2012;67:1289-1295.
  8. Tinazzi E, Puccetti A, Patuzzo G et al. Schnitzler syndrome, an autoimmune-autoinflammatory syndrome: report of two new cases and review of the literature. Autoimmun Rev. 2011;10:404-409.
  9. Neel A, Henry B, Barbarot S et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler syndrome: a french multicenter study Autoimmunity. Reviews. 2014;13:1035-1041.
  10. Eiling E, Moller M, Kreiselmaier I et al. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol. 2007;57:361-364.
  11. Zuberbier T, Maurer M. Urticarial Vasculitis and Schnitzler Syndrome. Immunol Allergy Clin N Am. 2014; 34:141-147.
  12. De Castro FR, Masouye I, Winkelmann RK, Saurat JH. Urticarial pathology in Schnitzler’s (hyper-IgM) syndrome. Dermatology. 1996;193:94-99.
  13. Гатторно М. Криопирин - ассоциированный периодический синдром (репринт). Вопросы современной педиатрии. 2013;12 (1):57-62. https://doi.org/10.15690/vsp.v14i3.1372
  14. Caso F, Rigante D, Vitale A et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. International Journal of Rheumatology. 2013;Article ID513782,15pages. https://doi.org/10.1155/2013/513782
  15. Jain T, Offord CP, Kyle RA, Dingli D. Schnitzler syndrome: an under-diagnosed clinical entity. Haematol. 2013;98(10): 1581-1585.
  16. Claes K, Bammens B, Delforge M et al. Another devastating complication of the Schnitzler syndrome: AA amyloidosis. Br J Dermatol. 2008;158:182-184.
  17. Dalle S, Balme B, Sebban C et al. Schnitzler syndrome associated with systemic marginal zone B-cell lymphoma. Br J Dermatol. 2006;155:827-829.
  18. Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luna JL. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum. 2005;52:2226-2227.
  19. Gran JT, Midtvedt Q,Haug S, Aukrust P. Treatment of Schnitzler syndrome with anakinra: report of three cases and review of the literature. Scand J Rheumatol. 2011;40:74-79.
  20. Asli B, Bievenu B, Cardoliani F et al. Chronic Urticaria and Monoclonal IgM gammopathy (Schnitzler syndrome). Report of 11 cases treated with Pefloxacin. Arch Dermatol. 2007;143:1046-1050.
  21. Billey T, Beldjerd M, Popa L, Lassoued S. Schnitzler syndrome: a dramatic improvement with anakinra. Presse Med. 2010;39: 1338-1339.
  22. Krause K, Feist E, Fiene M, Kallinich T, Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol. 2012;129:848-850.
  23. Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome:an open-label study. Allergy. 2012;67:943-950.
  24. De Koning HD, Schalkwijk J, van der Meer JW, Simon A. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol. 2011;128: 1352-1354.
  25. Vanderschueren S, Knockaert D. Canakinumab in Schnitzler syndrome. Semin Arthritis Rheum. 2013;42:413-416.
  26. Krause K, Tsianakas A,Wagner N et al. Efficacy and safety of canakinubab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. 2016; J Allergy Clin Immunol. 2016 Sep 19. pii: S0091-6749(16)30968-X. https://doi.org/10.1016/j.jaci.2016.07.041
  27. Federici S, Martini A, Gattorno M. The central role of anti-IL-1 blockade in the treatment of monogenic and multi-factorial autoinflammatory diseases. Frontiers un Immunology. 2013;4:351.
  28. Masters SL, Simon A, Aksetijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Ann Rev Immunol. 2009;27:621-668.
  29. Eiling E, Schroder JO, Gross WL et al. The Schnitzler syndrome: chronic urticaria and monoclonal gammopathy — an autoinflammatory syndrome? J Dtsch Dermatol Ges. 2008;6:626-631.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies